Filing Flows › Acadia Pharmaceuticals (ACAD) › Guidance history
Acadia Pharmaceuticals (ACAD) guidance history: what it guided and what it reported
Acadia Pharmaceuticals gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance twice and lowered it once.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.2B–$1.3B (May 6, 2026) → raised $1.2B–$1.3B (Aug 4, 2026) → raised $1.3B–$1.3B (Nov 4, 2026) | — | to be reported | — |
The latest quarter
Acadia Pharmaceuticals, Q3 2026: revenue $342M (+23% year over year), operating margin 21.0%, net earnings $53.5M, operating cash flow $11.5M. The chart follows the revenue to costs, profit and cash.
Questions
Does Acadia Pharmaceuticals beat its guidance?
Acadia Pharmaceuticals gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance twice and lowered it once.
How often does Acadia Pharmaceuticals raise guidance?
Its earnings releases raised guidance twice and lowered it once since May 6, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.